Mannan-binding lectin-associated serine protease-2

Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial

Retrieved on: 
Tuesday, March 23, 2021

Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month.
  • The I-SPY COVID-19 Trial is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative.
  • The pulmonary and critical care investigators leading the I-SPY COVID Trial uniformly endorsed narsoplimab and made it a high-priority candidate for the trial.
  • Narsoplimab is Omeros lead antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement.

Omeros Hires Nadia Dac as Chief Commercial Officer

Retrieved on: 
Tuesday, January 26, 2021

Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer.
  • In this role, Ms. Dac will be responsible for all commercial operations at Omeros, including overseeing preparations for the commercial launch of narsoplimab, the companys mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor.
  • Were pleased that Nadia has joined our senior leadership team, said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.
  • She joins Omeros from her most recent role as the chief commercial officer at Alder Pharmaceuticals where she built the commercial team to launch Vyepti in the migraine prevention market, which later was acquired by Lundbeck.

Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients

Retrieved on: 
Thursday, September 3, 2020

The panel discussed the emerging evidence that endothelial injury and the activation of the lectin pathway of complement are central drivers of the acute respiratory distress syndrome (ARDS) and thrombosis seen in critically ill COVID-19 patients.

Key Points: 
  • The panel discussed the emerging evidence that endothelial injury and the activation of the lectin pathway of complement are central drivers of the acute respiratory distress syndrome (ARDS) and thrombosis seen in critically ill COVID-19 patients.
  • Narsoplimab, Omeros investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key effector of the lectin pathway of complement, was identified as a potentially highly effective therapy to treat critically ill COVID-19 patients.
  • Omeros previously announced positive results from the treatment with narsoplimab of six critically ill COVID-19 patients under a compassionate use protocol.
  • All patients initially required mechanical ventilation and, following treatment with narsoplimab, all recovered, survived and were discharged from the hospital.

Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome

Retrieved on: 
Monday, August 10, 2020

Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), in the treatment of COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS), a severe and life-threatening symptom of COVID-19.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), in the treatment of COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS), a severe and life-threatening symptom of COVID-19.
  • Narsoplimab also has been evaluated in patients in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), another often-lethal thrombotic disorder associated with endothelial damage.
  • In its pivotal HSCT-TMA trial, narsoplimab-treated patients demonstrated marked improvement in laboratory and clinical endpoints and unexpected survival.
  • Omeros management will host a webcast and conference call to present the results of a compassionate-use study evaluating narsoplimab in the treatment of COVID-19 patients with ARDS.

Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System’s Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria

Retrieved on: 
Wednesday, September 25, 2019

Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria (i.e., high levels of plasma proteins in the urine) and inflammation.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria (i.e., high levels of plasma proteins in the urine) and inflammation.
  • The article, published in Frontiers in Immunology and entitled Absence of the Lectin Activation Pathway of Complement Ameliorates Proteinuria-Induced Renal Injury, can be accessed online at https://www.frontiersin.org/articles/10.3389/fimmu.2019.02238/full .
  • Both MASP-2-deficient and MASP-2 inhibitor-treated animals demonstrated marked renoprotection and reduction in inflammation from proteinuria with significantly less tubulointerstitial injury when compared to isotype antibodytreated controls.
  • Omeros lead MASP-2 inhibitor narsoplimab is in Phase 3 clinical programs for the treatment of IgA nephropathy and of atypical hemolytic uremic syndrome.

Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab

Retrieved on: 
Wednesday, July 31, 2019

Omeros Corporation (Nasdaq: OMER) and Lonza (SWX: LONN) today announced a long-term manufacturing agreement for commercial production of narsoplimab, Omeros lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), also referred to as OMS721.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) and Lonza (SWX: LONN) today announced a long-term manufacturing agreement for commercial production of narsoplimab, Omeros lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), also referred to as OMS721.
  • Omeros and Lonza have successfully partnered under a multi-year manufacturing agreement for the clinical supply of narsoplimab.
  • The new multi-year agreement secures a source of commercial quantities of narsoplimab for use following anticipated regulatory approvals.
  • Lonza has worked closely with us to accelerate the timing of our BLA and MAA submissions, and were confident in Lonzas ability to produce and maintain the highest quality commercial supply of narsoplimab.